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ABSTRACT
The human Myc proto-oncogene protein (MYC) is
a transcription factor that plays a major role in the
regulation of cell proliferation. Deregulation of MYC
expression is often found in cancer. In the last years,
several hypotheses have been proposed to explain
cell type specific MYC target gene expression patterns
despite genome wide DNA binding of MYC. In a
recent publication, a mathematical modelling approach
in combination with experimental data demonstrated
that differences in MYC-DNA-binding affinity are
sufficient to explain distinct promoter occupancies and
allow stratification of distinct MYC-regulated biological
processes at different MYC concentrations. Here, we
extend the analysis of the published mathematical model
of DNA-binding behaviour of MYC to demonstrate that
the insights gained in the investigation of the human
osteosarcoma cell line U2OS can be generalized to other
human cell types.
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INTRODUCTION
The human MYC gene codes for a transcription factor
called Myc proto-oncogene protein (in the following
abbreviated with MYC) that is involved in a variety
of cellular processes, including regulation of cell
proliferation [1, 2]. Increased expression levels of MYC
contribute to cancer development and are associated
with tumour aggressiveness [3]. Several studies
suggest that MYC binds to a specific DNA motif termed
enhancer box (E-box), with a consensus sequence of
CACGTG, and thereby regulates the transcription of
specific target genes [4, 5]. More recent experiments
using chromatin-immunoprecipitation (ChIP) and
ChIP-sequencing experiments [6–9] demonstrated
that MYC binds to almost all promoters, enhancers
and intergenic sites with an open chromatin structure,
independent of the presence of E-boxes [10, 11].
Despite this global DNA binding, MYC-dependent
tumours seem to harbour a specific set of up- and
down-regulated MYC target genes.
Two seemingly conflicting hypotheses have been
proposed to explain these observations [12, 13]. One
hypothesis, termed the general amplifier model [7,
8], suggests that MYC globally enhances transcription
and that specific gene expression arises indirectly due
to regulatory feedback and feedforward loops. The
alternative hypothesis suggests that a large portion of
MYC binding to DNA is non-productive with respect to
transcriptional regulation resulting in a specific set of
regulated genes [14, 15]. Global changes in mRNA
levels in this model are the consequence of physiological
and metabolic changes induced by specific sets of
regulated genes.
In our recent study, we proposed that the divergent
hypotheses can be reconciled in the new hypothesis
that specific gene expression profiles arise from
different affinities of MYC-DNA binding [11]. We used
a mathematical modelling approach in combination
with extensive experimental data to show that
differences in affinity are sufficient to explain the distinct
promoter occupancies observed in ChIP-sequencing
experiments for physiological and tumour-specific
MYC concentrations. Moreover, the promoter affinities
estimated from experimental data determine the
impact of MYC concentration changes on target gene
expression and they allow a stratification of distinct
MYC-regulated cellular processes at different MYC
concentrations. We also suggested that interactions
between MYC and promoter-bound factors may
increase promoter affinities, which can serve as a
molecular mechanism of context-specific modulation of
MYC-dependent transcriptional responses of individual
genes [13].
Our published model of MYC-DNA binding was
parameterised to represent U2OS cells. It was
comprehensively analysed with respect to the influence
of its parameters, such as assumed affinities and
proportion of heterochromatin, on the occupancy of
E-boxes by MYC. Many other human cell types differ
in several aspects from U2OS cells. For instance, their
karyotype and/or the fraction of E-boxes in their genome
may deviate due to single-nucleotide polymorphisms
(SNPs), larger structural variations, segmental deletions
or copy number variations, to name a few [16–
19]. We here present an extended analysis of our
published mathematical model of MYC-DNA-binding
[11] to demonstrate that the insights gained in the
investigation of U2OS cells may be generalized to other
human cell types as well.
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Figure 1: Extended analysis of the mathematical model of MYC-DNA-binding. A) Schematic representation of the
mathematical model. A detailed mathematical description of the model is provided in [11]; in brief, MYC can reversibly bind
to either consensus E-boxes or unspecific binding sites on the DNA. B) Impact of total MYC levels on occupancies of E-boxes (red
curves) and unspecific binding (blue curves) sites shown for particular combinations of genome sizes and E-box frequencies.
METHODS
Mathematical modelling
We use the mathematical model 1 as described
earlier ([11] and Appendix 1 therein). Briefly, MYC
can reversibly bind to either consensus E-boxes or
unspecific binding sites on the DNA. For convenience,
we renamed the two published parameters KNNNNNN
and [NNNNNNtotal] as KU and [Utotal] in our study.
Steady-state solutions were calculated by setting all time
derivatives in the model equations to zero and solving
the resulting algebraic equation system numerically. All
calculations were performed using Mathematica 10.2
(Wolfram Research, Inc.).
RESULTS
The published mathematical model describes the
reversible association of MYC with either consensus
E-boxes or unspecific DNA binding sites. It was
parameterised to represent U2OS cells. Two kinds of
parameters are considered in the model: (I) dissociation
constants (KEbox, KU) interpreted as inverse measures
of affinity of MYC-E-box-binding and unspecific MYC
binding to DNA, respectively (Figure 1A), and (II) total
numbers of molecules and binding sites ([MYCtotal],
[Eboxtotal], [Utotal]).
In our analysis, we consider the dissociation constants
(KEbox, KU) as cell type independent biochemical
properties and keep them fixed to their published values.
The impact that changes of these dissociation constants
have on occupancies was comprehensively explored in
our earlier study [11]. In contrast to the dissociation
constants, total numbers of molecules and binding sites
are certainly cell type specific and are varied in our
analysis.
MYC quantification in different human cancer cell lines
yielded roughly 105 to 106 molecules per cell [7, 11]. A
generally accepted estimate of mammalian transcription
factors is 104-106 molecules per cell [20]. Hence, to
cover all probable cellular conditions, we vary [MYCtotal]
over a rather broad range in our analysis (Figure 1B).
We also consider different numbers of E-boxes
and genome sizes than were assumed in case of
U2OS cells (9.3*105 molecules and 9.5*109 molecules,
respectively). The total genome length of a stereotypic
human cell is approximately 3 billion base pairs, which
enumerates to about 3*109 hexameric binding sites
([Utotal]) in a haploid cell and about 6*109 sites in a
diploid cell (Figure 1B, panels in left column and middle
column, respectively). In the human reference genome
on average 1 consensus E-box is found in approximately
every 104 hexameric binding sites (Figure 1B, panels in
upper row), i.e. [Eboxtotal]=9.3*105 molecules in U2OS
cells.
An alternative, likewise plausible estimate of [Eboxtotal]
can be derived from the notion that MYC regulates the
expression of 15% of all human genes [21]. Given that
the number of human protein-coding genes is in the
order of 2*104 [22] we can estimate about 3000 MYC
regulated genes. For simplicity, let us now presume that
each promoter of these genes harbours a consensus
E-box, we can roughly estimate an average frequency
of 1 consensus E-box in every 106 hexameric binding
sites (Figure 1B, panels in bottom row).
Having thus confined the parameter space of our
model to plausible ranges, we next explore the impact
of total MYC levels on occupancies of E-boxes and
unspecific DNA binding sites for different combinations
of genome sizes ([Utotal]) and E-box frequencies
([Eboxtotal]/[Utotal]). Our analysis demonstrates that for a
given genome site changes in the frequency of E-boxes
over orders of magnitude hardly affect the dependency
of E-box occupancy on cellular MYC levels (Figure 1B;
compare red curves in upper panels vs. bottom panels).
It also shows for very high amounts of MYC (>106
molecules) that haploid cells can realise a visibly higher
E-box occupancy compared to diploid cells or cells with
even larger genomes such as U2OS cells. Note that
for higher affinities of MYC to E-boxes, e.g. due to
binding of promoter-bound factors, these changes of
E-box occupancies can occur also at lower total MYC
concentrations. In contrast, the occupancy of unspecific
binding sites is hardly influenced by changes in total
MYC level under all considered combinations of genome
size and E-box frequency (Figure 1B; blue curves).
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DISCUSSION
Most cells in the human body harbour a diploid
karyotype. Cells may however differ in the number of
promoters with transcriptional capacity, for instance by
restricting the frequency of E-boxes available for MYC
binding. Our analysis demonstrates that a change in the
frequency of E-boxes in a cell has only minor impact on
their occupancy by MYC. This may indicate that silencing
of a large proportion of MYC target gene promoters,
for instance by chromatin remodelling, hardly affects
the occupancies of the remaining unsilenced promoters.
Also preventing MYC binding to certain promoters by
any other mechanism will not influence the remaining
target gene promoters. The reason is that the impeded
MYC molecules in such a scenario predominantly bind
to the unspecific binding sites that are in vast excess
over E-boxes. In fact, most MYC (more than 95% of
total MYC) is bound to unspecific binding sites in all
our model simulations. The observed low occupancy
of unspecific binding sites is simply due to the large
number of these sites compared to total MYC molecules.
We conclude that cell type specific differences in total
E-boxes hardly matter in the analysis of the model
for a given genome size. Differences in genome
size between haploid, diploid and U2OS cells seem
to influence E-box occupancies at certain total MYC
concentrations depending on the affinity of MYC. The
presented results therefore demonstrate the robustness
of the model behaviour with respect to parameterisation
indicating that our previous insights and conclusions can
be generalized to other human cell types as well.
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